Mabion
Poland - KonstantynówBiotechnology
Focus: Mabion is a Poland-based biotech company specializing in monoclonal antibodies for immunology and oncology indications. The company is publicly traded and currently advancing three Phase 3 programs.
Profile data last refreshed 21h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Mabion
AI assessmentNot HiringNo open roles listed right now. Follow Mabion to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Rituximab
Rheumatoid ArthritisClinical Trials (1)
NCT02468791MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
Phase 3Help build intelligence for Mabion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.